Mankind Pharma Limited (NSE:MANKIND)

India flag India · Delayed Price · Currency is INR
2,163.30
-23.70 (-1.08%)
Mar 9, 2026, 3:30 PM IST
Market Cap902.80B -12.5%
Revenue (ttm)139.14B +19.5%
Net Income17.79B -12.8%
EPS43.10 -15.2%
Shares Out412.81M
PE Ratio50.62
Forward PE38.75
Dividend2.00 (0.09%)
Ex-Dividend Daten/a
Volume825,818
Average Volume490,739
Open2,131.00
Previous Close2,187.00
Day's Range2,108.30 - 2,170.80
52-Week Range2,012.30 - 2,716.50
Beta0.18
RSI54.90
Earnings DateMay 22, 2026

About Mankind Pharma

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin a... [Read more]

Sector Healthcare
Founded 1991
Employees 19,620
Stock Exchange National Stock Exchange of India
Ticker Symbol MANKIND
Full Company Profile

Financial Performance

In fiscal year 2025, Mankind Pharma's revenue was 122.07 billion, an increase of 18.98% compared to the previous year's 102.60 billion. Earnings were 19.91 billion, an increase of 4.08%.

Financial Statements